Risperidone versus olanzapine in patients with schizophrenia and schizoaffective psychosis;Risperidon versus olanzapin bei patienten mit schizophrenie und schizoaffektiven psychosen

Nervenheilkunde

Volumn 19, Issue 5, 2000, Pages 110-112

  Conley, R R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ADULT; AGITATION; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOIDISM; SCHIZOPHRENIA; SHORT SURVEY; STATISTICAL ANALYSIS;

EID: 1642618064     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. Beasley Jr CM, Sanger T, Satterle W et al. Olanzapine versus placebo: results of a double-blind, fixed dose olanzapine trial. Psychopharmacology 1996; 124: 159-67.
2. Beasley Jr CM, Tollefson G, Tran P, Street J. Olanzapine versus placebo and haloperidol: acute phase of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-23.
3. Chouinard G, Jones B, Remington G, Bloom D et al. A Canadian multicenter placebo controlled study of fixed dosis of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1987; 7: 377-84.
4. Kasper S, Küfferle B. Comments on article by Tran and collegues, "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders". J Clin Psychopharmacol 1998; 18, 4: 353-4.
5. Schooler NR. Comments on article by Tran an collegues, "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders". J Clin Psychopharmacol 1998; 18, 2: 174-5.
6. Tran PV, Hamilton SH, Kuntz AJ, Andersen SW, Beasley C, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17, 5: 407-18.